NCT03719729: An overdue trial by New York Medical College
This trial is overdue. It was due to report 4 years, 1 month ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT03719729 |
|---|---|
| Title | A Phase II Study of Rifaximin (Xifaxan) for Patients With Sickle Cell Disease (SCD) |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 22, 2018 |
| Completion date | Feb. 22, 2020 |
| Required reporting date | Feb. 21, 2021, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 1495 |